123: SEVERE LYMPHOPENIA ACQUIRED DURING CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER: INCIDENCE AND EXTERNAL VALIDATION OF A PREDICTION MODEL
| العنوان: | 123: SEVERE LYMPHOPENIA ACQUIRED DURING CHEMORADIOTHERAPY FOR ESOPHAGEAL CANCER: INCIDENCE AND EXTERNAL VALIDATION OF A PREDICTION MODEL |
|---|---|
| المؤلفون: | T Kroese, J Jairan, J Ruurda, S Lin, R Mohan, S Mook, S Haitjema, I Hoefer, N Haj Mohammad, R Van Hillegersberg, P Van Rossum |
| المصدر: | Diseases of the Esophagus. 35 |
| بيانات النشر: | Oxford University Press (OUP), 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Gastroenterology, General Medicine |
| الوصف: | Background and aim The incidence of grade 4 lymphopenia in patients treated with chemoradiotherapy (CRT) according to Chemoradiotherapy for Oesophageal cancer followed by Surgery Study (CROSS) regimen is unclear. The primary aim was to determine the incidence of grade 4 lymphopenia during CROSS for esophageal cancer. Secondary aims were to externally validate a prediction model for grade 4 lymphopenia and compare overall survival between patients with and without grade 4 lymphopenia. Methods Patients who underwent CRT for esophageal cancer between 2014 and 2019 were eligible for inclusion. Patients with a planned radiation dose of 41.4 Gy (CROSS) or 50.4 Gy (‘extended-CROSS’) and concurrent carboplatin and paclitaxel were included. The primary outcome was the incidence of grade 4 lymphopenia during CRT defined according to Common Terminology Criteria for Adverse Events version 5.0 (i.e. lymphocyte count nadir Results A total of 219 patients were included of whom 176 patients (80%) underwent CROSS and 43 patients (20%) extended-CROSS. The incidence of grade 4 lymphopenia was 11% in CROSS and 33% in extended-CROSS (P Conclusion The incidence of grade 4 lymphopenia is significantly higher in esophageal cancer patients receiving extended-CROSS compared to those receiving CROSS. The prediction model demonstrated good external performance in the setting of the CROSS-regimen and could be used to identify patients at high-risk for grade 4 lymphopenia who might be eligible for lymphopenia–mitigating strategies. |
| تدمد: | 1442-2050 1120-8694 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_________::7b50b4246321cc5f33b80ab00c7ef280 https://doi.org/10.1093/dote/doac015.123 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi...........7b50b4246321cc5f33b80ab00c7ef280 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 14422050 11208694 |
|---|